su-11248 has been researched along with Diabetic-Retinopathy* in 1 studies
1 other study(ies) available for su-11248 and Diabetic-Retinopathy
Article | Year |
---|---|
Discovery of Novel Small-Molecule Antiangiogenesis Agents to Treat Diabetic Retinopathy.
Diabetic retinopathy is the leading cause of blindness which is associated with excessive angiogenesis. Using the structure of wondonin marine natural products, we previously created a scaffold to develop a novel type of antiangiogenesis agent that possesses minimized cytotoxicity. To overcome its poor pharmaceutical properties, we further modified the structure. A new scaffold was derived in which the stereogenic carbon was changed to nitrogen and the 1,2,3-triazole ring was replaced by an alkyl chain. By comparing the bioactivity versus cytotoxicity, compound Topics: Angiogenesis Inhibitors; Angiopoietin-2; Animals; Cell Survival; Diabetic Retinopathy; Disease Models, Animal; Down-Regulation; Drug Design; Drug Stability; Glucose; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred C57BL; Neovascularization, Physiologic; Phosphatidylinositol 3-Kinases; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Triazoles | 2021 |